Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2021 Oct;53(4):1004-1014. doi: 10.4143/crt.2020.973. Epub 2021 Jan 29.
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea.
Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals.
Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001).
In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future.
人乳头瘤病毒(HPV)相关口咽癌(OPC)的发病率有所增加,其分期和最佳治疗方法具有挑战性。本研究通过问卷调查,探讨了根据 N 分期对 T2 期 OPC 存在争议的治疗策略,并确定了韩国多学科专家的意见。
韩国头颈部肿瘤学会口咽治疗指南小组委员会制定了 5 种 OPC 场景,并分发给多学科治疗医院的专家。
来自 45 家机构的 65 名专家做出了回应。对于 HPV 阳性 T2N0M0 患者,67.7%的受访者选择手术,随后进行根治性同期放化疗(CCRT)或单纯放疗。对于 T2N1M0 HPV 阳性患者,专家专业对初始治疗方案的选择存在显著差异;53.9%的受访者选择手术,39.8%的受访者选择根治性 CCRT。对于 T2N3M0 期 HPV 阳性晚期患者,50.0%的受访者选择 CCRT,33.3%的受访者考虑诱导化疗(IC)作为初始治疗。CCRT 和 IC 更常用于 HPV 相关 OPC 病例(p=0.010)。多学科的差异表现为,头颈部外科医生和肿瘤内科医生倾向于选择手术,而放射肿瘤医生更倾向于选择根治性 CCRT(p<0.001)。
在本研究中,对于淋巴结阴性的 OPC 患者首选手术,随着淋巴结转移的进展,倾向于选择 CCRT,并进行 IC。根据分期和 HPV 状态,临床实践模式因专家专业的不同而存在差异。未来需要多学科的共识指南。